Jul 2 |
(GOVX) - Analyzing Geovax Labs's Short Interest
|
Jun 27 |
GeoVax Partners with Allucent to Conduct Phase 2b Clinical Study of Next-Generation COVID-19 Vaccine Candidate with Funding from BARDA
|
Jun 18 |
GeoVax stock rockets 50% on BARDA award for COVID-19 vaccine
|
Jun 18 |
GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company's Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1
|
Jun 7 |
GeoVax files to sell 1.61M shares of common stock for holders
|
May 29 |
GeoVax to Present at BIO International Convention 2024
|
May 17 |
GeoVax to Raise Approximately $1.3 Million of Gross Proceeds in Offering Priced At-the-Market
|
May 15 |
GeoVax Labs, Inc. (GOVX) Q1 2024 Earnings Call Transcript
|
May 14 |
GeoVax GAAP EPS of -$2.47 beats by $3.09
|
May 14 |
GeoVax Reports First Quarter 2024 Financial Results and Provides Business Update
|